Alejandro González Veliz/LinkedIn
Jun 23, 2026, 09:36
Alejandro González Veliz: Key Takeaways from the 2026 ACC/AHA Dyslipidemia Guidelines
Alejandro González Veliz, Interventional Cardiologist at Institute of Cardiology and Cardiovascular Surgery, shared a post on LinkedIn:
“Dyslipidemia management is entering a new era.
The 2026 ACC/AHA Guideline moves beyond LDL-C alone and embraces a more personalized approach to cardiovascular prevention.
- LDL-C goals are back
- Lp(a) should be measured at least once
- ApoB helps uncover residual risk
- Coronary calcium refines risk assessment
- Earlier intervention may change lifelong outcomes
The message is simple: identify risk earlier, treat smarter, and prevent ASCVD before the first event occurs.
Which update do you think will have the greatest impact on your daily practice?

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 16, 2026, 15:35Jim Hoffman: Could Blood Purification Change the Fight Against Cancer?
-
Nov 16, 2026, 15:16How Do Artificial Hearts Affect Platelet Function? – Platelets Journal
-
Nov 16, 2026, 15:10Assessing Coagulation Activation in DOAC – Treated Patients – JTH
-
Nov 16, 2026, 15:00Davide Antonio Mei: Should Anticoagulation Continue After AF Ablation?
-
Nov 16, 2026, 14:55Danielle Boyle: Beyond Platelet Counts – Why Patient Stories Matter
-
Nov 16, 2026, 14:28Jan Sloves: The Future of Vascular Ultrasound
-
Nov 16, 2026, 13:49Bahman Rasouli: A Rare Vascular Manifestation of Recurrent Papillary Thyroid Carcinoma
-
Nov 16, 2026, 13:28Muhammad Danyal: Platelet Patterns in Hepatitis B and C
-
Nov 16, 2026, 12:52Frank Nocken: Alzheimer’s Research Expands Beyond Amyloid-Based Treatments